Sönmez, M. T. Et Al. 2025. Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study. Multiple Sclerosis and Related Disorders , vol.101 .

Sönmez, M. T., YETKİN, M. F., Mehdiyev, D. A., Köseoğlu, M., Mungan, S., Kale, N., ... Terzi, M.(2025). Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study. Multiple Sclerosis and Related Disorders , vol.101.

Sönmez, Meryem Et Al. "Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study," Multiple Sclerosis and Related Disorders , vol.101, 2025

Sönmez, Meryem T. Et Al. "Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study." Multiple Sclerosis and Related Disorders , vol.101, 2025

Sönmez, M. T. Et Al. (2025) . "Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study." Multiple Sclerosis and Related Disorders , vol.101.

@article{article, author={Meryem Tuba Sönmez Et Al. }, title={Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study}, journal={Multiple Sclerosis and Related Disorders}, year=2025}